First results from the primary analysis population of the phase 2 study of erdafitinib (ERDA; JNJ-42756493) in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRalt).

被引：65
|
作者：
Siefker-Radtke, Arlene O.
Necchi, Andrea
Park, Se Hoon
GarcAa-Donas, JesAs
Huddart, Robert A.
Burgess, Earle Frederick
Fleming, Mark T.
Rezazadeh, Arash
Mellado, Begona
Varlamov, Sergei
Joshi, Monika
Duran, Ignacio
Tagawa, Scott T.
OHagan, Anne
Avadhani, Anjali Narayan
Zhong, Bob
De Porre, Peter
Loriot, Yohann
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[2] Ist Nazl Tumori, Milan, Italy
[3] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Seoul, South Korea
[4] Clara Campal Comprehens Canc Ctr CIOCC, Madrid, Spain
[5] Inst Canc Res, Sutton, Surrey, England
[6] Carolinas HealthCare Syst, Levine Canc Inst, Charlotte, NC USA
[7] US Oncol Res, Virginia Oncol Associates, Norfolk, VA USA
[8] Norton Healthcare, Louisville, KY USA
[9] Inst Investigac Biomed August Pi Sunyer IDIBAPS, Barcelona, Spain
[10] Altai Reg Canc Ctr, Barnaul, Russia
[11] Penn State Canc Inst, Hershey, PA USA
[12] Hosp Univ Marques Valdecilla, Santander, Spain
[13] Weill Cornell Med Coll, Div Hematol Med Oncol, Dept Urol, Meyer Canc Ctr, New York, NY USA
[14] New York Presbyterian Hosp, New York, NY USA
[15] Janssen Res & Dev, Spring House, PA USA
[16] Janssen Res & Dev, Beerse, Belgium
[17] Inst Gustave Roussy, Villejuif, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.4503
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4503
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Efficacy and safety of derazantinib (DZB) in patients with metastatic urothelial carcinoma (mUC) with activating FGFR1/2/3 genetic aberrations (GA): Results from the phase 1b/2 FIDES-02 study
    Necchi, A.
    Todenhoefer, T.
    Deville, J-L
    Hackl, M.
    Marszewska, M.
    Mckernan, P.
    Saulay, M.
    Engelhardt, M.
    De Santis, M.
    EUROPEAN UROLOGY, 2023, 83 : S783 - S783
  • [32] Interim results of fight-201, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with metastatic or surgically unresectable urothelial carcinoma (UC) harboring fibroblast growth factor (FGF)/FGF receptor (FGFR) genetic alterations (GA)
    Necchi, A.
    Pouessel, D.
    Leibowitz-Amit, R.
    Flechon, A.
    Gupta, S.
    Barthelemy, P.
    Maio, M.
    Zhu, X.
    Asatiani, E.
    Serbest, G.
    Zhen, H.
    Loriot, Y.
    ANNALS OF ONCOLOGY, 2018, 29
  • [33] Insights into second-line (2L) systemic treatment (tx) receipt in patients (pts) with metastatic urothelial carcinoma (mUC): Results of a retrospective observational study in Germany
    Niegisch, G.
    Kearney, M.
    Krieger, J.
    Osowski, U.
    Deiters, B.
    Maywald, U.
    Wilke, T.
    Grimm, M-O. J.
    ANNALS OF ONCOLOGY, 2024, 35 : S1154 - S1154
  • [34] Efficacy and safety of derazantinib (DZB) in patients with metastatic urothelial carcinoma (mUC) with activating FGFR1/2/3 genetic aberrations (GA): Results from the phase 1b/2 FIDES-02 study.
    Necchi, Andrea
    Todenhoefer, Tilman
    Deville, Jean-Laurent
    Haeckl, Manuel
    Marszewska, Michalina
    McKernan, Phil
    Saulay, Mikael
    Engelhardt, Marc
    De Santis, Maria
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [35] Final results of a phase I study of cabozantinib (cabo) plus nivolumab (nivo) and cabonivo plus ipilimumab (Ipi) in patients (pts) with metastatic urothelial carcinoma (mUC) and other genitourinary (GU) malignancies
    Nadal, R.
    Mortazavi, A.
    Stein, M.
    Pal, S. K.
    Davarpanah, N.
    Parnes, H. L.
    Ning, Y. M.
    Cordes, L. M.
    Lin, J.
    Bagheri, M.
    Linderberg, L.
    Berniger, M.
    Steinberg, S. M.
    Moore, T.
    Lancaster, T.
    Aviles, M.
    Costello, R.
    Bottaro, D. P.
    Dahut, W. L.
    Apolo, A. B.
    ANNALS OF ONCOLOGY, 2017, 28
  • [36] Nivolumab (NIVO) plus gemcitabine-cisplatin (GC) vs GC alone for previously untreated unresectable or metastatic urothelial carcinoma (u/mUC): Chinese population analysis results from the phase III CheckMate 901 trial
    Ye, D.
    He, Z.
    Zou, Q.
    Wang, Z.
    Xu, D.
    Zhang, P.
    Dong, H.
    Liu, Z.
    Guo, J.
    Cao, X.
    Yuan, X.
    Chen, J.
    Hu, Y.
    Tsai, Y-C.
    Kang, W.
    Filian, J.
    Wang, L.
    Luo, H.
    ANNALS OF ONCOLOGY, 2024, 35 : S1511 - S1511
  • [37] A phase 3, open-label, randomized study of nivolumab plus ipilimumab or standard of care (SOC) versus SOC alone in patients (pts) with previously untreated unresectable or metastatic urothelial carcinoma (mUC; CheckMate 901).
    Galsky, Matt D.
    Powles, Thomas
    Li, Shengting
    Hennicken, Delphine
    Sonpavde, Guru
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [38] A phase 3, open-label, randomized study of nivolumab plus ipilimumab or standard of care (SoC) vs SoC alone in patients (pts) with previously untreated unresectable or metastatic urothelial carcinoma (mUC; CheckMate 901).
    Galsky, Matt D.
    Powles, Thomas
    Li, Shengting
    Hennicken, Delphine
    Sonpavde, Guru
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [39] Analysis of circulating tumor DNA (ctDNA) from the phase II BLC2001 trial of erdafitinib in locally advanced or metastatic urothelial carcinoma (mUC) to identify markers of intrinsic resistance to fibroblast growth factor receptor (FGFR)-targeted therapy
    Siefker-Radtke, A. O.
    Loriot, Y.
    Necchi, A.
    Huddart, R. A.
    Burgess, E. F.
    Rezazadeh, A.
    O'Hagan, A.
    De Porre, P.
    Avadhani, A.
    Monga, M.
    Cherkas, Y.
    Moy, C. H.
    Santiago-Walker, A.
    ANNALS OF ONCOLOGY, 2020, 31 : S584 - S584
  • [40] Pembrolizumab (pembro) as first-line therapy for advanced/unresectable or metastatic urothelial cancer: Preliminary results from the phase 2 KEYNOTE-052 study
    Balar, A.
    Bellmunt, J.
    O'Donnell, P. H.
    Castellano, D.
    Grivas, P.
    Vuky, J.
    Powles, T.
    Plimack, E. R.
    Hahn, N. M.
    de Wit, R.
    Pang, L.
    Savage, M. J.
    Perini, R.
    Keefe, S.
    Bajorin, D.
    ANNALS OF ONCOLOGY, 2016, 27
12345